Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
出版年份 2018 全文链接
标题
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
作者
关键词
-
出版物
ONCOGENE
Volume -, Issue -, Pages -
出版商
Springer Nature America, Inc
发表日期
2018-08-03
DOI
10.1038/s41388-018-0421-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
- (2016) Andrew R Green et al. BRITISH JOURNAL OF CANCER
- Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
- (2016) Priyanka Sharma et al. CLINICAL CANCER RESEARCH
- Resetting cancer stem cell regulatory nodes upon MYC inhibition
- (2016) Silvia Galardi et al. EMBO REPORTS
- The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma
- (2016) H. K. Bid et al. MOLECULAR CANCER THERAPEUTICS
- Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide
- (2016) A. Sorolla et al. Nanoscale
- Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
- (2016) Shaokun Shu et al. NATURE
- Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer
- (2016) Roman Camarda et al. NATURE MEDICINE
- OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors
- (2016) L A Jung et al. ONCOGENE
- Loss of TRIM33 causes resistance to BET bromodomain inhibitors through MYC- and TGF-β–dependent mechanisms
- (2016) Xiarong Shi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MYC regulates the antitumor immune response through CD47 and PD-L1
- (2016) S. C. Casey et al. SCIENCE
- Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
- (2016) Alison M. Kurimchak et al. Cell Reports
- Different promoter affinities account for specificity in MYC-dependent gene regulation
- (2016) Francesca Lorenzin et al. eLife
- Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
- (2016) Céline Berthon et al. Lancet Haematology
- Small-molecule inhibitors of the Myc oncoprotein
- (2015) Steven Fletcher et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy
- (2015) Elias E. Stratikopoulos et al. CANCER CELL
- Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas
- (2015) Munevver Cinar et al. LEUKEMIA RESEARCH
- Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP
- (2015) Liangliang Shen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells
- (2015) Maria Patrizia Mongiardi et al. Scientific Reports
- Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
- (2015) Timothy J. Stuhlmiller et al. Cell Reports
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Therapeutic Effects of an Anti-Myc Drug on Mouse Pancreatic Cancer
- (2014) Dimitris Stellas et al. JNCI-Journal of the National Cancer Institute
- Inhibitor of MYC identified in a Krohnke pyridine library
- (2014) J. R. Hart et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis
- (2014) Daniela Annibali et al. Nature Communications
- Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
- (2013) L. Soucek et al. GENES & DEVELOPMENT
- Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function
- (2013) A S Beltran et al. ONCOGENE
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models
- (2012) P. J. Roberts et al. CLINICAL CANCER RESEARCH
- MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
- (2012) Dai Horiuchi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- 18F-Fluorodeoxy-glucose Positron Emission Tomography Marks MYC-Overexpressing Human Basal-Like Breast Cancers
- (2011) N. Palaskas et al. CANCER RESEARCH
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance
- (2011) T. W. Miller et al. CLINICAL CANCER RESEARCH
- The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy
- (2011) Mauro Savino et al. PLoS One
- In Vitro Cytotoxicity and In Vivo Efficacy, Pharmacokinetics, and Metabolism of 10074-G5, a Novel Small-Molecule Inhibitor of c-Myc/Max Dimerization
- (2010) D. M. Clausen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- MYC regulation of a “poor-prognosis” metastatic cancer cell state
- (2010) Anita Wolfer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phenotypic screening of phylomer peptide libraries derived from genome fragments to identify and validate new targets and therapeutics
- (2009) Paul M Watt Future Medicinal Chemistry
- Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice
- (2008) Jianxia Guo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer
- (2008) M. N. Dickler et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started